EPO and chronic kidney disease: In CKD patients, however, sustained inflammation in renal fibrosis becomes the major contributor to EPO deficiency, as the damaged REPs in fibrotic kidneys transform into myofibroblasts, causing the concomitant repression of their ability to produce EPO [28].